Skip to main content

Guidelines Updated for Diagnosis, Management of Focal Liver Lesions

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 23, 2024.

via HealthDay

TUESDAY, July 23, 2024 -- In a clinical guideline issued by the American College of Gastroenterology and published online in the July issue of The American Journal of Gastroenterology, updated recommendations are presented for the diagnosis and management of the most common focal liver lesions (FLL).

Catherine Frenette, M.D., from the Family Health Centers of San Diego, and colleagues used the best evidence available to make diagnosis and management recommendations for the most common FLLs.

The authors recommended multiphasic contrast-enhanced imaging, preferably magnetic resonance imaging (MRI) or computed tomography performed with late arterial, portal venous, and delayed phases in patients with FLL of uncertain etiology. In patients with hepatic adenomas, discontinuation of oral contraceptives or intrauterine devices that are hormone-impregnated is recommended. Weight loss is suggested for overweight or obese patients with hepatic adenomas. To accurately distinguish hepatic adenomas from other benign or malignant liver lesions, multiphasic liver imaging (preferably MRI) is suggested over standard cross-sectional imaging modalities. Discontinuation of exogenous hormones is suggested and weight loss advised, if applicable, in women with hepatic adenomas <5 cm. Continued imaging surveillance is recommended every three to six months for at least one year in patients with cirrhosis or chronic hepatitis B who meet criteria for hepatocellular carcinoma surveillance and have a suspected hemangioma.

"Despite the radiographic results, patients will continue to rely on their providers to make the best recommendations for ongoing care, which in the ideal scenario is the reassurance that no further follow-up is required, especially in patients without underlying comorbidities," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Consistent Physical Activity Linked to Reduced All-Cause, CVD Mortality

FRIDAY, July 11, 2025 -- Consistently and increasingly accumulated physical activity (PA) is associated with a reduced risk for all-cause and cardiovascular disease (CVD)...

Increased Liver Enzyme Levels Seen With Use of Cannabidiol in Adults

THURSDAY, July 10, 2025 -- Use of cannabidiol (CBD) within the range consumers are taking with unregulated CBD products is associated with increased liver enzyme levels, according...

Majority of Patients With Lyme Disease Do Not Follow Up With Clinician

THURSDAY, July 10, 2025 -- Only 34 percent of patients with erythema migrans >5 cm are positive for Lyme disease by a standard two-tier testing (STTT) algorithm, and of...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.